Ahmed H. Salem, Ph.D.
Affiliations: | 2010 | Social, Administrative, and Clinical Pharmacy | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Pharmacy, Biostatistics BiologyGoogle:
"Ahmed Salem"Parents
Sign in to add mentor| Richard C. Brundage | grad student | 2010 | UMN | |
| (Demonstration of pharmacometric applications to anti-infective chemotherapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Polepally AR, Ng JW, Salem AH, et al. (2020) Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Clinical Pharmacology |
| Karol SE, Alexander TB, Budhraja A, et al. (2020) Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. The Lancet. Oncology |
| Alhadab AA, Salem AH, Freise KJ. (2020) Semi-Mechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. Clinical and Translational Science |
| Kaufman JL, Baz RC, Harrison SJ, et al. (2020) Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 38: 8511-8511 |
| Goldsmith KC, Verschuur A, Morgenstern DA, et al. (2020) The first report of pediatric patients with solid tumors treated with venetoclax. Journal of Clinical Oncology. 38: 10524-10524 |
| Gopalakrishnan S, Menon R, Chyla B, et al. (2020) Abstract 3024: Relationship between venetoclax concentrations and undetectable MRD in patients with chronic lymphocytic leukemia Cancer Research. 80: 3024-3024 |
| Kurumaddali A, Salem AH, Agarwal SK. (2019) A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival. Journal of Cancer. 10: 5427-5433 |
| Deng R, Gibiansky L, Lu T, et al. (2019) Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia & Lymphoma. 1-10 |
| Dave N, Gopalakrishnan S, Mensing S, et al. (2019) Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis. Clinical and Translational Science. 12: 625-632 |
| Agarwal S, Gopalakrishnan S, Mensing S, et al. (2019) Optimizing Venetoclax Dose in Combination with Low Intensive Therapies in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: An Exposure-Response Analysis. Hematological Oncology |